title: Reslizumab: First Global Approval.
abstract: Reslizumab (Cinqair(®)) is a humanised monoclonal interleukin-5 (IL-5) antibody developed by Teva that has been approved in the USA for patients aged ≥18 years as add-on maintenance treatment for severe asthma with an eosinophilic phenotype. IL-5 stimulates the production, activation and maturation of eosinophils and is therefore thought to play a role in the development of bronchial hyper-responsiveness. This article summarizes the milestones in the development of reslizumab leading to this first approval for add-on maintenance treatment of severe asthma with an eosinophilic phenotype.
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand. dru@adis.com.
authors.forename: Anthony
authors.initials: A
authors.lastname: Markham
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D004804:Eosinophils / Q000187:drug effects*; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C508599:IL5 protein, human; D015848:Interleukin-5; C515492:reslizumab